Opicinumab: is it a potential treatment for multiple sclerosis?
Research output: Contribution to journal › Editorial › peer-review
Colleges, School and Institutes
Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS.
|Journal||Annals of Translational Medicine|
|Early online date||5 Mar 2020|
|Publication status||E-pub ahead of print - 5 Mar 2020|